ACE2 and ovarian serous cystadenocarcinoma: A higher expression of ACE2 predicted better outcomes for disease-free survival and overall survival in tumours such as renal clear cell carcinoma, hepatocellular carcinoma, and ovarian serous cystadenocarcinoma [7].